

January 25, 2018

Company name: RIBOMIC Inc.  
Stock code: 4591  
Listing: TSE, Mothers Market  
URL: <http://www.ribomic.com/en/>

### Confirmation of therapeutic effect of anti-chymase aptamer after onset of heart failure

We have been conducting joint research with Professor Shinji Takai of the Department of Innovative Medicine, Graduate School of Medicine, Osaka Medical College, with regard to in-house developed agent, RBM003 (anti-chymase aptamer).

As a result, we have reported that the administration of this aptamer significantly improved cardiac function in an acute phase model of myocardial infarction by coronary artery ligation using hamsters.

We conducted a hamster experiment in which this aptamer was administered only after coronary artery ligation to determine whether this improvement in cardiac function was due to pre-ligation administration (i.e., prophylactic) or post-coronary ligation administration (i.e., treatment), which corresponds to the onset of myocardial infarction in humans.

The results showed that "post-administration" showed marked improvement in cardiac function without "pre-administration".

These results indicate that "post-administration" of this aptamer may contribute to the maintenance of adequate cardiac function in patients with acute heart failure.

There are only a limited number of drugs available for acute heart failure, and we plan to promote RBM003 clinical-development through licensing or business alliances with pharmaceutical company.

The President and CEO of RIBOMIC is scheduled to give a lecture on the above results at the "APTAMERS 2018" held in Oxford, UK, from 11 to 12 April this year.

( <http://libpubmedia.co.uk/aptamers-2018/> )

### Profile of RIBOMIC

RIBOMIC is a bio-venture company centered on drug discovery. The company is engaged in the field of aptamer therapeutics, which is a type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company's core drug development platform, can be used for the development of many types of aptamer drugs. RIBOMIC is dedicated to the discovery of drugs that target the broad field of unmet medical needs, which encompasses pain, eye disorders, fibrosis and many other problems.

【Inquiries:Corporate Planning Department +81-3-3440-3745】